An update on PARP inhibitors--moving to the adjuvant setting (Q38257125)

1 September 2017

1 reference

title

An update on PARP inhibitors--moving to the adjuvant setting (English)

1 reference

1 September 2017

2

Evandro de Azambuja

0 references

author name string

Amir Sonnenblick

series ordinal

1

1 reference

1 September 2017

Hatem A Azim

series ordinal

3

1 reference

1 September 2017

Martine Piccart

series ordinal

4

1 reference

1 September 2017

language of work or name

English

0 references

publication date

7 October 2014

1 reference

Nature Reviews Clinical Oncology

1 September 2017

published in

1 reference

1 September 2017

volume

12

1 reference

1 September 2017

issue

1

1 reference

1 September 2017

page(s)

27-41

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

1 September 2017

1 reference

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Dissecting the heterogeneity of triple-negative breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Genome maintenance mechanisms for preventing cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

The therapeutic potential of poly(ADP-ribose) polymerase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

The role of poly(ADP-ribose) in the DNA damage signaling network

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Hallmarks of 'BRCAness' in sporadic cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Iniparib plus chemotherapy in metastatic triple-negative breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Comprehensive molecular portraits of human breast tumours

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Poly(ADP-ribose): novel functions for an old molecule

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

PARP inhibitors: polypharmacology versus selective inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Functions of poly(ADP-ribose) polymerase in controlling telomere length and chromosomal stability.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Loss of androgen receptor in aging and oxidative stress through Myb protooncoprotein-regulated reciprocal chromatin dynamics of p53 and poly(ADP-ribose) polymerase PARP-1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

PARP-3 and APLF function together to accelerate nonhomologous end-joining

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Poly(ADP-ribose) polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Tankyrase-targeted therapeutics: expanding opportunities in the PARP family

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Comparing poly (ADP-ribose) polymerase inhibitors with standard chemotherapy in BRCA-mutated, recurrent ovarian cancer: lessons learned from a negative trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

DNA repair: the importance of phosphorylating histone H2AX.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Targeted therapy for cancer using PARP inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Resistance to therapy caused by intragenic deletion in BRCA2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Secondary mutations inBRCA2associated with clinical resistance to a PARP inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Mechanisms of resistance to PARP inhibitors--three and counting.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

A Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.163

Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25286972

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25286972

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25286972

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCLINONC.2014.163

1 reference

1 September 2017

1 reference